PRINT • ONLINE • EMAIL DELIVERED • LIVE EVENT
T
HE GOLD STANDARD
providing broad coverage and
incisive analysis of the issues,
events, trends and strategies shaping
pharmaceutical business, marketing and
sales returns with a robust 2016 lineup
designed to meet the needs of our
pharmaceutical marketing audience.
e
The Magazin
The Maga
zine of Ph
armaceut
ical Busin
ess
TOP 50 PH
ARMACEU
TICAL COM
PANIES
and Mark
eting • me
dadnews.c
om • Octo
ber 2015
• Volume
34 Number
5 • $100
Joe Benko,
an
retired after Army veteran who rec
en
a 40-year ca
reer as a dra tly
an enginee
rin
fts
hepatitis C g company, was diagn man for
after dona
osed with
ting blood
bank. Joe su
to a loc
spects he co
a blood tra
ntracted the al blood
nsfusion wh
virus from
en he was
vaccinations
a child, or fro
required du
m
ring the Vie
tnam War.
After being
diagnosed
, Joe avoid
treatment
ed interfero
in fear of the
n
sid
associated
with the the e effects commonly
rap
of his friend
and neighbo y. At the insistence
he went to
r,
a local cardi
a live
er 2 • $100showed the dis r specialist for a biops ologist,
e 34 Numb
y, which
ease had ca
cirrhosis.
used mild
2015 • Volum
liver
om • April
s.c
ew
dn
da
S
IONS AGENCIE
T
A
IC
N
U
M
M
O
HEALTHCARE C
ess
eutical Busin
of Pharmac
ting • me
and Marke
Joe’s physi
cian suggest
ed a newly
treatment
approved
calle
offer a bette d Harvoni that could
r chance of
potentially
being cured
few weeks
of treatmen
an
t, his viral loa d, after a
dramaticall
y. Three mo
d dropped
nths after co
therapy, the
mp
vir
blood, mean us was undetectable leting
in Joe’s
ing he was
cured.
The Magazine of Pharmaceutical Business and Marketing • medadnews.com • February 2015 • Volume 34, Number 1 • $25
AGENDA 2015
A whole new ball game
Company
of th
T e Year
The business of marketing pharmaceuticals today would be almost
unrecognizable to a visitor from five years ago; the industry’s fate
hangs on how industry leaders respond to all this change.
By Joshua Slatko josh.slatko@medadnews.com
o an industry insider who magically fell asleep in 2010 and
woke up as the ball dropped in
Times Square to ring in 2015,
the pharmaceutical industry
might be nearly unrecognizable. Five
years ago the Affordable Care Act had just
been passed and signed by the president;
today its consequences have flowed out
in all directions, transforming the way
healthcare is provided and paid for. Five
years ago mobile web was just catching
on; today it accounts for more than 60
percent of web traffic. The pharmaceutical executive of five years ago would be
overwhelmed by all the new audiences,
new decision makers, new expectations,
new media, new data and sources of information of today; even for those of us
who have not been napping for the past
five years, it can all be a little overwhelming. For this year’s Agenda overview,
Med Ad News spoke with a long list of
industry insiders, the people who have
to deal with this sort of tranformational
change every day. Here are the trends
that they told us would be most important for pharma marketers in 2015.
From the perspective of the healthcare
consultants at PwC, the changes wrought
in the marketplace by ACA and the rise
of new provider and payer entities will
drive nothing less than a change in the
real meaning of value for pharmaceutical
companies and their constituencies, leading to a greater focus on real outcomes
accompanied by real data.
“The shift of risk in selection and payment for therapeutic treatment to various provider entities introduces new
variables that the pharmaceutical product industry will need to orient towards,
namely quality and total cost of care,”
says Warren Skea, principal, PwC. “No
T
TOP 10 PIPELINES
Biologic medicines and immunotherapy
are front and center amongst many of
the R&D strategies and platforms for the
industry’s leading developers.
The
Acquisition
Game
Hum
ira du
best
-selli ring 2014
ng pr
escrip remaine
d
tion
med the world
icine
’s
.
Inside
he payer as provider is looking
for materially different shifts in
clinical quality impact and the
total cost of care.
longer will pharmaceutical product companies’ strategy that focuses on physician
directed therapy based on their clinical
knowledge and payors processing claims
based on their approved cost of treatment
analysis, define and determine their sucTopping the list of crucial developments cess.”
Nothing less than a new definition of valfor pharma marketers in 2015 is the continuing transition in how health services ue through outcomes-based evidence that
are provided and paid for. Today’s brand proves such value is what stands between
manager is faced with a bewildering ar- success and failure for pharma companies
ray of acronyms – the Accountable Care now, Skea suggests. The very definition of
Organization (ACO) and the Integrated payer has begun to radically shift to a vaDelivery Network (IDN) are the two riety of new models that are both consolimost prominent of many – and each of dating and adopting risk for cost (bundles,
these has its own unique decision making capitation) and care (quality, outcomes), to
processes and value definitions. Pharma say nothing of employers and consumers
companies are having to learn on the fly who are the primary funding sources. And
how to deal with all these new decision this shift is driving a corresponding change
makers, a process that is causing perhaps in payer expectations.
“The payer as provider is looking for
the largest single shift in selling strategy
materially different shifts in clinical qualin the entire history of the industry.
The changing marketplace
Inside
ity impact and the total cost of care, both
Amgen
AstraZeneca
upstream and downstream, as related to
Biogen Idec
any product therapy,” Skea says. “ProBristol-Myers Squibb
viders also want to know which patient
Celgene
cohorts will receive the greatest impact
Gilead Sciences
Merck
from the day a therapy is authorized, not
Novartis
after months or years. Determining the
Pfizer
holistic, incremental, and/or avoidable
Roche
costs of care, across a broad range of actual operating costs incurred by delivery
SALES-FORCE EFFECTIVENESS:
systems outweighs the incremental disCHANGE IS THE CONSTANT
count that typifies the current state.”
So outcome study proof and the docuPharma sales forces continue to evolve,
The Ma
mentation of cost and quality differences
trying to meet physicians’ information
gazine
labotheMagazine
is going to have to take place in
The
and survive in a healthcare
needs
of Pharmaceut
of Pha
ical
by the and
ratory of every day clinical delivery where
altered
environment radically
Business
rmaceu
Marketing • medadnews
therapeuSPEC
impact
; and a new player
life
Act
real
Care
of
ordable
Aff
variables
the
.com • June 2015
tical
IAL RE
of value
enters the sales-force training field.
• Volume 34, Number
Busine
tic performance. “The validity
SPECIAL
REPORT
3 • $25
PORT
ss and
— TOP 100 BIOTECHN
measured is best spoken for by provider
— TO
Marke
OLOGY COMPANI
industry leaders that have the trust and
ES
ting
P 200
stature of peers across their community,”
• me
MEDIC
dadnew
Skea says. “This has become necessary to
INES
individuals
s.com
with Type
avoid the skepticism that can often aclatory Type III SMA, II and non-ambu• Aug
company product company-led studies.
as well as a reducust 201
tion in medical
complications associ5 •
Sova
ated with the disease.
Volum
ldi
The investigationa
DIRECT TO CONSUMER
e 34,
into sec vaulted
HUMAN
Num
ime is designed to l medicine olesoxThe impact of Viagra’
ber 4
protect the health
s
most
on
recent
THE MANNY AWARDS:
DTC
motor nerve cells.
of
campaign has brand
d
place
• $25
Olesoxime has been
managers talking
ROARING BACK
granted Orphan Medicinal
in
about the “humanity”
of their
Product desfull ye its first
ignation for treating
communications
SMA
The Manny Awards of 2014 marked the
by
the
ar
European Medicines
Agency and Orphan
25th year of this event, and strongly
the ma on
Drug Designation
continued traditions while bringing it into
by FDA.
rket;
Roche announced
Ha
a new era.
This shift to provider system definitions
FIRST
in
December
rvo
2014
a deal to acquire
YEAR
for outcome value has put a premium
Dutalys GmbH,
NOT
a priYOU
challe ni is
vately held biotech
need to
upon the productByindustry’s
The lead R FATH AFTER
company with headAndrew Humphreys
nging
quarters in Vienna,
• andrew.humphreys@med
ing memER’S LAU LAUNC
abandon the vertically integrated model
phar
Austria.
Hu
maceutic
Dutalys
H:
adnews.com
is dedicated to the
bers NCHES
mira
class
that was committed to a pre-determined
al indu of the
intro
velopment of fully discovery and destry’s
the 20 for
standard duced
value definition over to a highly collabornew
antibodies based human, bi-specific
for laun during 2013 compoun
15
ative outcome model that is intent upon
on their proprietary
ch succ
have
crown sales
DutaMab technology.
discovering value as an ongoing journey.
set a d
ess.
new
antibodies developed The bi-specific
.
In this way product companies can more
with this platform
are designed to provide
PATIENT COMMUNITI
responsibly convert to risk based contract
novel, best-inES:
class molecules for
By And
PATIENT INFLUENCE
agreements where outcomes and the data
several therapeutic
CONTINUES TO RISE
rew Hu
fields. This transaction
The growth of communities
to support them can be trusted and opmphre
such as Inspire
lights Roche’s leadership further highand PatientsLikeMe,
erationalized across the provider com- not on outcomes or value. In an environcoupled with FDA’s
ys • and
therapeutic antibodies. in developing
recent guidance on
ment that is aligned around cost-reducmunity.”
rew.hum
social media in pharma,
he prec
A conventional bi-specifi
point to how patients
phre
In addition to the consolidation of pro- tion and fee-for-value, winning on price
will increasingly
c monoclo2012 ipitous
ys@med
nal
antibody
For
merit
commoditization.
to
directly
pate
leads
pharma’s
assa
models
is
a biotechnologically
vider networks into ACO/IDN
attention
adnews
to the
nt cliff
ulted
engineered artificial
and rollout of the federal and state-level brands that are competing with an effec.com
protein consisting
lion tune of Big Pha of ty
fragments of two
of
to pate
up to
and new
rma
wor
exchanges, experiments with outcomes- tive generic, there are fewer options to
different monoclonal
antibodies and consequently
next nt expiratdrug saleth of pres $53 bil- were app
therape
THE MANNY AWARDS
based reimbursement and the muscle- avoid this margin squeeze, but for many,
riatic
can bind
utic biol
jectedhighest tota ions. 201s potentiacription Adminis roved
to two different antigens.
The 26th annual Manny
flexing of the leading pharmacy benefits the path forward looks like a business
Crohn’sarthritis
The DutaMab
ogical
tration by the U.S
Awards
5 repr lly lost high
l
could figure
technology platform
took place on April
est
,
prod
esen
of since
managers to negotiate exclusive deals partner model. As healthcare in the Unit23rd at Pier Sixty
time be lost due $44 billithen, with ts the approva total everduring 201. Food and ucts erate to disease, ankylosing
for the development varies by allowing
he to
in New York City
U.S.
moves away from fee-for-sered States
put general
biotechnolog
,
with pharma is continuing
plaq
of fully human biseve
arth
(there
4,
uting ls by
Dru
y by the world’s
a
to exp on in
muc however
spondy
specifi
FDA
move towards
is undergoing
will need to largest
h
sale prower the seco g avai ritis. In re), and ue psorias
costs. vice,
healthcare
downward pressure onarena
biotechnology the c antibodies where each arm
a re-pharma
litis
pact less wid , the brunt ired pate s that massiveto the year in 199 e 53 new
company, approaches
ndthe Uni juve
labl
of
antibody demonstrates
Roche. The
disease
to Swiss
as
Ormesher of cloespread is exp nts.
6).
This, says CEO Davidcord-breaking
nile is (mo ,
M&A more
to seve e for
ly
cycle partnership
C trea sales
ted
pharma and simultaneous
high affinity
are tiedmore than
giant spent aboutand cure.”
for challenges
erup Rx dru Also con drug
ected This
the industry.
re), axiaulcerati States, idiopath dtme
prevention, management
and After
$8.3 billion on
serlook inc., presents both
to biot sixty than the
not
to be 2013 and nts that tion from g grow trib- pediatr
the targets, excellent binding against both
August 2014
l spo ve colitis Humira ic
generating
Joryet
Patrickdespite
perc
position,
acquisition
Taking a similar
its role
to assert M&A
pharma
is also ic Crohn’s
opportunities
stability, and
ndyloar
continu began
new th is
valuedfor
the Uni facing echnolog ent of 2012 imis
the manufacturin
(mo
California
at $235 billion during activity
biotech offi
Encer of
administrative
g properties. This good
firm’s
es to in four hepatiti a enthesit approve disease thropath derate
and value.
ted Stat biosimil y dru the sale
2014,dan,
Humir
leading
mar
the chief
U.S. biotech sector
drug
prospect
process
th-quart s Abb
surg
gs
enables
(severe) y, and
kets
s
that
the treatment of disease
produced
is-re d in
company,
notbelieves
core, a Quintiles having
a lea
compamost pharma
yet produced
e dur
“At this
more than
desp es and ar com that
As a
$100point,
any nisms that
revenue marketplace
billion
mechads the
. Hum
ing 201 er com Vie’s secolated arththe EU
deals
result, ite losi in som petition are For
that point in
commands
could not
the shift in the at
of vendor,”
role during
to playinthe
nies continue
first-quartime. But three
to erod
ter 2015.
pack
5.
ng excl e othe
pan
nd-qua ritis. for ped ira
months later, InterMune’s
gen
the
in
Industry
conventional bi-specifibe addressed with
indianalysts
model amongEsbriet
the EM y rece
a different operating
“Most conAccordi iatric
PATIEN
Ad News.
Med
Ormesher
note that
sales e $16 erics hav usivity r major was the third con
rter
c
antibodies.
mosttold
ntly
(pirfenidone)
M&A
Another private company
billion
A for
this
was FDA-approve
e bee
last between three
in
received2015 repo ng to
spec
top-selli secu
T AD
STIL
on volume-discounts,
priced cycles
tracts fiare
d for6 treat- by
ifi
L NO
to ing idiopathic continued on page
n fore 2015. During
ve years.
a
acquisition
tive
in pres
Wit year.
With 2014
Roche during 2014
pain cally desi new Hum clearanc rt, the
The infl RX FOR HEREN
expecteh most
criptioncasted ated glob2014, theng prescripyear, Hu
was that of Sanin the newest cycle, being the first year tients with IPF pulmonary fibrosis. Pa- taris Pharma
and redu gne
PATI
CE:
ENT
the biotech industry
gradually lose the
patie uence of
d to blockbu
betw
d to ira form e from
al sale biologic tion med mira
in August. The Copenha-dru
Also
term
ADH
ce
is anticipated to continue
nt
con
ability
phar
een
to breath as fibers
g Eis
gen, Denmark-bas
s
tinue ster biot
ma com ERENCE
limited, adherenc
icine. nounce during injectio reduce ulation
fill up their lungs.
petitionminus
wheeling and
ed
ai Co. markete of about therapy gen
dealing at record
ech bran
to
d resu first-half n volu injectio
Another biotech acquisition
company pioneeredbiopharmaceutical
III
levels,
and therebut phar e problem panies on
HBA WOMAN OF
, the significan thrive
ous
$12
rs
n
its proprietary
by
ma does is part
lysts firms projecting with some ana- during the
THE YEAR experiencin
the
pharma t bios in the ds app injectioAdminis AbbVie .86 billi er- ty trial inve lts from 2015, me.
are
enco
past year was that Roche Locked Nucleic Acid
The Healthcare Businesswomen’s
of Hum stigatin
tered
a growth rate of
Global
Abb
nea
on
VIS
n,
imil
rove
g
urage things the have a icularly
(LNA)
/bio
about 20 percent
Inc.
of
a
Vie anTro- that has
ar com r ease
d for Humira as a sub
role
better
for the next two years. phos in January 2015 for up
Association hosted
contributed to an platform
projecteprescrip substan tech indu
and Results ira in adu g the effiUAL-I, a
a vari
s.
its annual Woman of
to EUR era of
use of industry can to play
Since the last time
tial grow
emerging
470 million. A
cuta
dem
Phase
tion
nifi
cacy
lt
stry - tum The
d
ety (ada
RNA-targeting therapeutics.
Year (WOTY) event
conthe
med
do to
and
at the New York Hilton
tinue by vari drug sale
was published by this annual report company based privately held biotech new class
icine
th peri is anti or nec medicine of auto limumab ne- trol cantly lowonstratedpatients
This
ous
s.
with safeMidtown on May 14th
cent
)
Med Ad News two
imm
rosi
of
grow
led
in
stem
medicines
ered
Marseille,
od.
s
is
that
bod
indu
hav
s
has the potenuve
years ago, 14 of
uve
France, tial to address
une
ing,
Trophos’ proprietary
e
stry
grow rate annuall
the
Lau y drug factor alphs from the dis- gained orphitis or patients the dru itis.
at
hard-to-treat diseases
screening platana bee
th rate
generating biotech top 100 revenue- form generated
’ risk
g
visio
various therapeutic
y unti nearly a lysts ton ing Jannched inclass.
in
a mon anti- regulato
blockbu
an
of unc sigis a new
fields.
l 202
five
listing have been entities from that code TRO19622), olesoxime (product
rs for drug desin loss. Abb
oclonal men
more uary 200 the Uni
onSantaris’ LNA platform
crease ster prod
per0.
acquired, including
t
which
wav
gna
Aid
of
the
Vie
is being de- covery
former top 20
and drug disuveitis certain
veloped for spinal
investig tion from has
ucts e of first- ing the China, than 87 3, Hum ted Stat
ductivit in rese
members Elan
engine unites the
muscular
with
Corp. SMA is a
company’s pro(purchased by Perrigo
tory
in-class is used Brazil, countri ira is avai es dur
y. A totaarch and and a
Hum forms of ational U.S.
rare and debilitatingatrophy. prietary LNA chemistry
es
fi
Co.) and Cubwith its highly
l of 41 develop recent
ist Pharmaceutic
genetic specialized
across for trea and Aus includin lable in half 201lings are ira. U.S non-inf treatneuromuscular disease
als Inc. (bought
intrali
and
new
men
.
targeted
g
ting
most commonly
13 glob
drug discovery
Merck & Co.)
by diagnosed in
a. The Japan, the seco 5, follo expecte and EU ectious
molecul t proover
capabilities to
In
children.
d dur
ally app
win
regu
850,000
prod
ar enti
Another former top
Uni North
results with olesoxime Pivotal Phase II didates againstrapidly deliver drug canFor nd pivotal g positive
ing seco
la100 company ac- toid on, the Americ roved indi pati uct Hum firstmRNA and microRNA.
in SMA demonstud
quired since 2013
results ndstrated a beneficial
was InterMune
arthritisdrug is a and the cationsents uary ira globhalf 201 y.
effect on the main- As a result, scientists are able to
from
Inc. tenance of
markete
5,
develop
al
drug candidates
-Jun
Europe .
neuromuscular function
(modera
for diseases that
alm
e 201 sales of AbbVie
d
in difficult, or
repo
te to for rheu an Stro ost 9 perc
5 inte $6.65
impossible, to target are
severe), marnationa billion. rted
ng
with
ent
contemporary drug
pso- throughU.S. grow on an ope
l sale Janing antibodies and platforms includby dou out seco th for
rationa s rose
small molecules.
The
LNA platform is
major ble-digi nd-qua Humira con l basis.
designed to overcome
the limitations of
derm market t growth rter 2015, tinued
earlier antisense
1 MED
atol
cate
and
spu
siRNA technologies,
AD NEW
The ogy and gories:across all rred
S AUG
unique combination in particular via a
U.S
gast
rheu
thre
ent
UST 2015
of small size, high
coverin. compos roentero matolog e
binding affinity
to exp
ition
and metabolic stabillogy.
g
y,
ity that enables
of
equival ire dur adalimu
this new class of
mab matter
drug
course ent EU ing Dec
emb is schedupat1 MED AD NEWS
continued on page
by Apr in the patent
JUNE 2015
er
6
led
il 201 majorit is slated 2016. The
y of thos to run
8.
its
e cou
ntries
M&A activity througho
ut the industry is helping
the biotechnology
world soar to new heights.
T
T
conti
nued
on page
6
mk16
2016 MEDIA KIT
Insid
e
“In one word EXTRAORDINARY.
It has helped me in providing
new vision, new thoughts &
exclusive ideas.”
is the flagship publication of Outcomes, LLC,
a marketing and media company built to
quench the evolving consumption habits
of B to B audiences.
–CNS Marketing, Torrent Pharmaceuticals
“Great publication!
Read it every month.”
Twitter:
@medadnews
@PharmaLive
@ChristianeTrue
@DanRx
Daniel Becker
Brand Director
Andrew Humphreys
Director of Content
–Brand Manager, GlaxoSmithKline
Facebook:
/medadnewsmannyawards
/pharmalive
Joshua Slatko
Contributing Editor
“Med Ad News is very useful,
particularly the Top 100 lists.
I save those for reference.”
LinkedIn:
Med Ad News
PharmaLive
Christiane Truelove
Contributing Editor
–Marketing Director, Sanofi-Aventis, Inc
YouTube:
youtube.com/pharmalive
Med Ad News Audience – 16,500 Key Decision Makers in Pharmaceutical, Biotechnology, Medical
Device and Healthcare Communications. Bonus Distribution – 20,000 Influencers
Financial Mgmt
112
Financial Mgmt
Misc (Media, Marketing
Services, R&D, Licensing, IT)
Sales/Account
Management
378
Sales/Account
Management
1494
C-Level
(VP & Above)
1000 2000 3000 4000 5000 6000 7000 8000
Print
2480
C-Level
(VP & Above)
Product/Brand Mgmt/Marketing
/Advertising/Promotion
7135
0
2000
2784
524
Business Strategy
6456
Product/Brand Mgmt/Marketing
/Advertising/Promotion
0
Misc (Media, Marketing
Services, R&D, Licensing, IT)
925
Business Strategy
75
4000
6000
3550
10,533
8000
Bonus Digital
10000 12000
2016 Departments
n Sales and Marketing
editorial calendar 2O16
n Interactive & Digital Marketing
n Medicine Ave
n People On The Move
february
april
n Health Outcomes
Sales and Marke
ting
By Med Ad News
HEALTHCARE
COMMUNICATIONS
AGENCY ISSUE
TOP 10 PIPELINES
s AGENDA 2016
s SALES-FORCE SWEET ‘16
s MEDICAL ADVERTISING
HALL OF FAME
Ad Close: 1/16/16
Materials Due: 1/23/16
s
s
Ad Close: 3/09/16
Materials Due: 3/16/16
staff
Local market strat
egy
By Howard Brock
design and pullthrough via an
integrated app
roach
to a patient demogra
particular geograph phic common to a certain
chronic illnesses.
very market
Boston, Minnesotic market.
As the vulnerab
populatio
is
le Customization
making national unique, Pittsburgh representa, the Northwest, and social, ns are identified—based
of marketing
on local
cultural, and
examples of
cial or regional commer- that have more
economic determi- messages and tools
influential payers. markets nants—preventive
less than optimal.strategies Cleveland, and New
measures could
Boston, in place
be
companies would Instead, be characterized York, meanwhile, can those or access to treatment providedput When implementing
a local
from a local market
as markets with
who need it most.
benefit influentia
to egy, tools
more
and messages market stratstrategy that ensures
l academic
Smaller ACOs
customer-facing
will need to
medical
customized based
and
Miami, Atlanta,
teams have the
on the dynamics be
and Tampa are centers. ing to partner with IDNs might be will- the
framework, messages
right where
markets
pharma
in
physician
,
tools,
companies with local market. Messages in
to address adherenc
and training
s
that make sense
markets
making power have had more decision- unique
tighter reimburs
e issues based
for
and organized
ement, for example,
Through our worktheir markets.
are
customers lower market demographics. Areason the might be more reimburs
Campbell Alliance across the industry, typesmore open to partnerships.
socio-economic
with while in
ement focused,
Archeareas where
levels, for
like these, combined
across the inVentiv and our colleagues market
with additiona tend to see higher non-adhe example, clinical decisions physicians can make
Health organizat
considerations
l because people
rence rates
, the messages
have determin
and
ion
more
account, phymay not be able
will be
sician, and patient
ed
focused on clinical
their medicine
market strategy that applying a local the
segmentations,
. Resources may to afford tient support messages information. Pabasis for execution
form cused on
also be fo- in
approach across requires an integrated tactics.
will be applicabl
areas with higher
of
strategies
markets
the
e
and lations.
organization that
where
elderly popudresses all of the
Demogra
adhas been establishelimited patient support
background are phics related to racial
of the different unique functional needs Applica
Innovative new d.
customers and
tion of local market
conditions are also important, as some tal
technologies and
influencers.
more prevalent
channels are opening
strategy
digiin individuals of a particula
Local market strategy
the door to new
forms of customiz
r race.
defined
Adherence strategies
ation and
Implementing
must be personal- Consider a market archetype outreach.
ized, coordina
a successful
Across the United
in which an
organized customer
ted, and optimized
local mar- maceutic
ket strategy requires
States, many
has
. Phar- tocol
ent healthcare
companies to
differ- changes
over a set of affiliateda treatment prodynamics can
make simply al companies cannot afford
including the
be found, tomer across the organization.
throw money
to es to which
physician offichigh provider
The cus- adherenc
into every available
model must
a pharma manufact
concentration
and
not have access.
urer does
in cities like Pittsburg payer with key customer establish partnerships Instead, e program to see what
In this instance,
influential academic
works.
s and
an
h, the within
the ecosystem other influencers should be integrated adherence solution opportunities as well as peer-to-p media
medical centers
cities like Boston,
of a local market.
based
in Roles, messages
munications could
eer
the more active
tion to personali on data and segmentaoffer a solution. com, tools, and digital
employers in
role of tions—as
From a media
ze it to the
managing their
soluwell as product
costs in cities like
healthcare and
access strategies outreach effort then needs patient. The targeting technologstandpoint, improved
Seattle, and the
tactics—must
to be coordinated to
ies are able to
strictions on pharmac
strict re- market
be adapted for
ideneach patients. avoid overwhelming individua tify likely physicians by
environment.
eutical promotio
found in markets
their
With
And
l
ns port and
like Minneapolis.
adherence solutionspatient sup- a manufact the full range of channels at so that when a physician is geography
A local market
urer’s disposal
engaged in
healthcare
need to
aligned
is a geographic
which market
area in needs. to local patient demographics be ing digital messages, mail today—includ- Times, for information in the New York
drivers
example, it is possible
and
Pulling all of this
messages, phara common business combine to produce companie
through requires macy messages, etc.—the
tify the individua
to idenenvironm
s
danger
to
l
of creating a
reconsider how
ent that af- resources
fects patient care,
white noise effect. exists up an ad propertyas a physician and serve
they allocate
and coordinate
or marketin
and reimbursement.prescribing behaviors,
and train teams. the effort needs to be optimized Finally, that might be
relevant in that g content
ing the data to
be a city, a region, A local market could Establis
moment.
Alternatively,
see what works by trackor a state, or it
hment of custom
as physician-centric
doesn’t work in
and what cial
the sphere of
er
a given market
media networks
influence of an could be partnerships
sosegment and
customer.
organized
efforts redirecte or patient it is possible to identifygrow in popularity,
ingly.
d accord- encers
local market influA wide range
The
within those
ers exist, making of drivers and influenc- has ACA and the shift in payment
It may be possible online communities.
models Flexibili
increased the burden
to identify individua
example, marketseach market unique. For ganized
ty of customer-facin
by specialty or
experience varying
ls
customers, and on providers, orpatient type
g roles influencin
els of provider
s
payers to manage
lev- challengi
consolidation,
g their peers in who are truly
Facts & Figure
ng patient
Typically
while
markets may
those
organizations
have more complex some and more institutio populations. As more formly , companies will resource
online, opening affiliated
nized customer
ns and health
uni- sibility
orga- shift
the
s than others,
systems amountacross the US, deploying
the same feeding of creating digital ad boardsposinstitutions, integrate
including are to pay-for-performance models,
survey by MedPanel,
of
a
resources
to
in Seattle
content via the
or
or
increasingly worried
• According
they burgh or
wearables
as in Pitts(IDNs) and health d delivery networks populatio
emerging thought
Oklahom
areadiscussing
leaders.
City percent
physicians
relativeoftotheir
systems, physician
ns for which they about patient scale, such
groups, payers,
some
with 15
asapps
lack a solution
market
Another market
to manage them.
and
volume
contrasts
potentialhealth
or market
archetype may
This figure
ganizations (ACOs). Accountable Care Or, number
on average.
be char: acterized
of prescriptions,
Many
patients
ber of doctors,
demands of patientsThe expectations and tomers, of these providers, organized
of potential candidates
num- such as by a fragmented patient base,
staff
theornumber
number
with
News
Miami,
cusAd
and
patients
of
and
of
patients.
where the large
the influence of
local market strategy
payers are increasin
By Med
government—such
In aof patient
38 percent
Hispanic
openness
physicians saymodel,
base
42 percent
pharma
and
(ACA) complian as Affordable Care Act ceutical to partnerships with g their panies need flexibility
com- t A potential receives fragmented services.
not using a wearable
pharma- their
ce
benefi
to be
innovative solution
app could
to adjust
an able
regulations—can or state promotional solutionsmanufacturers to help
customer facing
not using
to offer an opt-in
may be
develop changing patients
also vary from
roles to a constantl
text messaging
market.
market to bination . Such solutions include
so.
y providing
marketpl
services
from doing
ace.
a comhealth education
of quality programs
is the brand most
With differenti
Finding managea
specific to an
The Apple Watch
, data genof. individual’s needs.
ble ways to address eration partnerships,
are aware
g, the
types serve• as al resourcin
This informati
local market differenc
arche- with
(82 percent)
shared investme
fuel improved
a starting
physicians
on can
nts
es can be challeng- in patient support and
point
conversations
are most
that familiar
ing. We have
be customiz
can aretors
between docadherence, and then
on and
However,
ed physicians
increased awarenes
addressed this
through localPhysicians
teams
market understa patients, helping patients
by setting up
challenge prove
s andand
ensure brand knowledg
e and
by a 2 to 1 margin.
advocacy
Fitbit,planning
tion
better
local market
to imnd the elements
public
ed with current
. In asatisfi
organiza
concept
perceptio
thatand
geograph
mildly
archetypes
that simplify the
is d
payer dominate
of their own care
y scores
and improve their
average only
the value of the integrate
te n.
Band
The issueapprecia
alignmen
d,
where
Microsoft
of
the
not
an
t
doctors
patient
overall
of
drive decision
ent customer
the differ- grow
In fact,
complian
do
outcomes.
products.
reps tocedrive
While we have
needs. One market,
making,
will only sense
for satisfaction
in can enable
would make
Bajaj
observed many
of allitwearables
ample,
ce engagem
to deploy
for ex- is critical importan
because ent.
highest
may possess
are
thefewer
and Jaideep
comexecute portions
personal,
physicians saypanies
meetingr outcomesadherence facing resources
customer
By Saby Mitra
un- tocustome
attributes
of academic medicala high concentration ts
an
of
two
the
the
clinical
on than in a
integrate
represen Local markets
market strategy,
and thelocal
metrics. prescribe
ease of use
force. This
that havetoan
that exertmany
greatphywhere panies
sales centers
examples of com-d
pharma
important:market
rs aremost
success
still the
ACO
influence
to deal ofthe
that have optimized
generate.
ity for a ACO-like) system
dominant decision
The keys
and control
opportun
the provider
or institution will(or an makers.
of data the devices
s sales rep access
tapped
over
their
utility
tion
deinnovacommun
view
be
through
to
tor
moreins
likely
ity,
a fully
open to creating
es.whereas another
Commercial “As long as tech companies rare.
the orchestra
may
al
sicians continue
compani
partnersh
drivenBy designing integrated strategy are
es adoptips
en-multiple
outsourcing apps
address
saleshave
academic enting tradition
challengi
to tatecoordiAs compani
a local market
and canas consumertacng patient
differentialwearables
faciliBy supplemcenters that
cline and the are influentia
begin to better
and pulling it
andpopulatio
with digital
strategy
remain
such
resourcin
l
more
but
orwill
visits
as
model
the
do
diabetes
ns,
grows
rep
g
rep
not
through via an
by allowing
pharma companie
sales exert control.
g across
these products
patients.and
Another market
their
vironment
markets,
marketin
Creative
approach, companie
integrated
can boost
adherenc
president,
s to easily
eutical person
may be influence
patient ed
five keys
e partnersh
nate sales
different
on-board
s can establish
and
presence of ACOs
orchestrator dreps
to
” says Jason LaBonte,
ips n,
byengagem
complex, pharmac
a fad,
customer
has pinpoint
orZS
the beent
ed partnersh
physicians
solutions
trust-facing
used to help ganizatio
pressure tics,or (or ACO-like
can
they engage
ntation:
ips
if
reach,
resource
that
files
’s
“But
constant
manage
change
zations,
impleme
that
l
found
and
)
pro- tion within
under
organiZS
align toMedPanel.
company
these patients.
their percepwhich,
es given
a particula
example, For
companies are
products, wearables
themselv
instance,torecognizi
ensure a successfu
their focusFor
key customers,
r market
d these
on quality ofoutcomes
differentiatemetrics
ar-of healthcare
recommen
The ability
performance.
patients, and
traffic to a
and controllin
ng that health chetype.
other stakehold
to quickly scaleas part
to find ways to
g costs,20
are affected not
ers. medadnews
down from
willpercent
impact on the that nearly
uptor
with the right
have an from
lace.
apps will be viewed
sales rep
sponsorship
only by biologifixtures.”
cal factors,
Secure
way physician
resources
in the marketp
permanen
but also by social
an organization and become
ement
tor rep.
website
provides Howard
s andcomes
tals operate andbrand’s
Further,
s. environm
the flexibility to
risk manag
and
senior
physician
Enter the orchestra
factors s, preferably
get reimbursed. hospian evolution
take ad- market Brock is head of commercial models and
tor rep is industry
As
ofand
executivevantage
interactions with
25 percent ental settings,
a particular opportun
shifts toward
a pharmaceutical
local
nearly
Senior
strategy for Campbell
The orchestra rep. This
arethe
new model
company
personalized medisalesthe
mitigate
d
Alliance. Additional
cine,
ity or contributors
could do a public-pr
for both
al
and
targeted
email open rates
risk of a negative
s leversinclude
vate compare
market-therapies
accountability i- will
partnersh
of the tradition
imporby sales reps,
with
be reasons,
couldsent
effectivenes
event.
be relevant
head-ip to
s, these
For outcomes,
identifyg atfunction
integrates sales, depart- for emails
ncies,Renee Selman, president, patient
sent bylevel
er salesialforce
the comwhenmunity
Adheris
rep compete
of sales rep
Health; Andrew Aromando,
shape the commerc
sales ng
outsourci
those
isand
er marketin
thought
with
who aredrive
customer-facing gy to to about 8 percent
of in much
the change
VP, business
aligned
plans.
executive
development,
to vulnerab
found that non-writ
broader and
ing and other
le to strategic
adopts
incentive
technolo
as it terms.
and
often
MED AD NEWS
leverages 30
quarters. ZS also double for physicians tant
organization
Jeanine O’Kane, managinginVentiv Selling Solutions;
hiring profiles
nnelAUGUST
ments and
2015 on rates
multicha
mindset in the
d
director,
ace
Biosector
integrate
conversi
Householder
2; and Leigh
ing early
to both face-to-f g orchestration.
, senior VP chief innovation
facilitate an
ent. The orchestra
are exposed
Engage marketand marketofficer, GSW.
nnel marketin
customer engagem help drive a more who
and multicha
and
Integrating salesthe key to the
can
plan
receiving
a
detailing
to
a
model
d
Create
boost
is
tor rep
ntally
ns – compare ications.
ing functions
approach and
tion model,
implement increme
commun
customer-centric ’s reach, engagement promotio
ensive vision
the orchestra
only one of these realize the benefits,
While a comprehimperative to success of g will play a vital role in
pharma company
Before they can os must integrate
nce.
marketin
is equally
to drive
and performa
is essential, it vision in incremental and
the sales team
however, pharmac
adopt an orempowering
that
companies
of pharma sales sales and marketing and a thoughtful, implement
manage the de- orchestration. As a result, beginning
using
Companies can
at the
Key to the future
the orto involve them
chestration model with buy-in from steps.and pace of change across
buy-in
and marketing
maturity need implementation to ensure
gree
d approach
a structured
of any
, the organize
ganization with
eutical industry
consists of three
stakeholder groups.
success.
on. And key
In today’s pharmac
model. This approacha traditional sales and
is differentiati
rator
es
success
the
transform
to
to
ent
orchest
key
stages
to implem model
g with the
tor rep.
themselves, compani
to differentiate their sales and mar- How
rep into an orchestrareps grow more in- Thrivin
rator rep
rep model
first stage,
a more orchest
the
need to integrate
interacIn
g
create
to
to
tions
rep orchesabout all the marketin
companies look
keting organiza impactful customer
enables
ities for sales and cusand
tion, they formed
As pharmaceutical
customers. This
ents The opportun
coordinated
by specialty
tor rep sits at implement sales rep orchestra customer tions with their
engagem
vary
,
will
orchestra
stronger
d
tration
mix. However
experience. The dynamic.
them to drive
rep becomes
first design integrate
channel affinity pharma comfor reps. Com- with physicians. Next, the
or- tomer’s
the heart of this global sales and mar- must
ent strategies
the specialty,
the marketing
technology,
report, engagem
According to
integrated with to influence fu- no matterespecially those with multiple
must also leverage
AccessMonitor
success more
s, multiple
n and begins the last stage, panies –
the U.S. panies plays a critical role in the
keting firm ZS’s
In
in their portfolio
physicians in
As cus- ganizatio
about half of e-to-severe restrictions which orchestrator rep model. trend ture marketing tactics.orchestrator of all brands r-facing teams and relatively
the
full
custome
multichannel
and preferences ents, the rep becomes a
placed moderat pharma sales reps in of
g engagements decent investment into
betomer behavior
nnel marketin
on visits from
g on the
the risk of falling
multicha
23 percent of more toward digital engagem
to
run
s
–
camarketin
g
tes with
their digital
access in
g tac- marketinthey remain tied to the status
2014. This compare
os need to grow reps with the and coordina
restricted rep
e of upcomin
pharmac
changing
hind if
By Christiane
prescribers who
timing and relevanc
to adapt to the
and equip sales
Truelove
• chris.truelo
s pabilities
quo and fail
use of alternate
ve@medadnews.com
2008.
a tics.
to maximize the
of digital resource
tor rep
marketplace.
The explosion directly or indirectly ability channels and help them creater.
the orchestra
early
Implementing
transforTest with anteam
access to digital relationship with the custome
has to some extent
organizational
,
create
a reduction in
digital
model requires
experience
es also must
careful planning
contributed to
companies
of meeting with
and involves
Pharma companitechnology analytics
marPharmaceutical
access inphysicians. Instead
tion us- mationleadership across sales and nts
data and
s can simply
strong
investme
such a robust cture to equip the sales team should test sales rep orchestra
reps, physician
digital sources,
ce model before keting organizations and
customer,
management.
an early experien
formation through . More than 90 per- infrastru
teams.
ree view of the
change
ing
sales
and
gy
ent
360-deg
a
across
little
’s engagem
digital with
nationally or
in the in technolo
as email or webinars
companies have
in the U.S. accessaccord- including the physician g. Further, it’s scalinga small team as a test group
Still, pharma
customers’
cent of doctors
marketin
a Using
stage enables choice but to adapt as their
their offices,
sales and ne
aldesign
from
with
ntation
to
ion
es
changed
of the highest-pow
percent
have
informat
initial impleme
t for compani
ent
calibrate, address
- alized
arma, and 67
and preferences
learn,
medicine
ered events
ip to and
hip managem
ing to eyeforph
nals point importanr relations
reimbursement tomake needs
leadersh
of the
easy ganizationa
care professio
permanently.
andBIO
ormay arise and
custome
this shift
most
that
2015
l
intuitive
design
is
imforcing
convention
issues
preferred
of U.S. health
and
that
and
any
leadership.”
inaccess,
as their
system
PhilThe event
scaling the new
The market driversand the most sucbefore
featured
to digital channels ion from pharma (CRM)for repsadelphia
did easily
so they can
interactive
changes
notbest
away,
actually
use of strations
to use
the future
are not going
take
emerging technologiedemonmodel.
makeinthe
source of informat
and place
provedof
the convencompanies in
tion
through
s being
center
sort
and insights. adapted for health care
itself, but uprthe
cessful pharma that integrate sales and
the evo-National
companies.
street at the iesnew
custome data
in extraordina
train yourry
drivers make
and
Museum of American
ways using
will be the ones and empower the orgical capabilit
tor a all available
Involve
These market
holograms,
ies’ technolo
Jewish
l
History,
g efforts
into an orchestra
that helpvirtual reality,
Compan
at Klick
reps 3D printing,
Health’sanalytics
sales
and large-scale
lution of the repin the pharmaceuticalExchange
inaugural preferfirst-level marketin r rep to drive more impactfu
include
projection
mapping. It is crucial that
also must
event. The e physicianIdeas
n the chestratoons with the customer, greater
necessary shift ZS estimates that by
reps determin invitation-o
event,
effec- For many attendees,
and champio
co-sponsor
sales
actions tonly
overall busis embracePresident
edbest
by BIO,
nextKlick
industry. In fact, percent of pharmaeffectively interacti
the
Health, was manager
on and better
Google andand
60
model toClinton
the majortor
repAfter
Veeva them.
es differentiati
will be ences
Systems, brought
draw.
2020, at least
medadnews
apologies
As compani
is orchestra
engage
gether
to- being
reps in the U.S. their
teams.
for on ness performance.
ntation
visionary
tively
two hours
sales
leaders
impleme
their
of
late,
and
ceutical sales
with
g
Clinton
focus
coach
piece
the
nation’s
shouldof the
top biopharma
The finalCEOs ent, which
includes
with marketin
work of the Clinton
they spoke
at ZS,
Photo Credit: Joe Schildhorn/B
orchestrating
Foundation
tools and
train their reps,
andgave
managemto explore
howd role
is an associate principal
emerging
a shout-out
change
technologie
capabilities, and
FA.com
enhance
to tion
easy Saby Mitra Bajaj is chairman of ZS’s board
a new,
s in
outgoing
and
field peers.
data
small portion
orchestra
rep
ntation
BIO
can
the
very
in
radia
President
,
cally
changeand CEO Jim
Jaideep
training
U.S. H-1B
andvisa
te change
the wayahealth
make the impleme
mindset
Today, however
orcheswider care
program that allows
, formerally,
is deliv-forgressman
the strive to Greenwood
ered
fostering
eutical reps orchestra
con- othAddition
and
foreign like 10
how
g and
of directors.
healthtion
care to
secure buy-in
to apply for large
of U.S. pharmac
marketinPresident
the sales force.
companies
into contractors
g the
for representin
ated of
8th District
work. transnumbers of here, years from now, and even if I’m not
extent. While
Pennsylvan
be incorpor
these visas and gave
change
Bill Clinton,
ap- the organiza
ia. “He
should
what I hope would
to the fullest
billedThe
is what
as the keya major employer
tion model.
g tration
is rapidly be- opportunity
customer-centricnote,
be happening.”
coming
orchestra
the
the marketin
an oxymoron in national
a frenzy
larg- attracted
Clinton’s
the local
teams often adopt
to lay off 250 tech
coverage
n mustofengage
from
politics, whose
rarely involve
news
workers, manageme speech not only went into
formatio
outlets,
severance
but other luminaries a moderate Republican,” Clinton
g budget:
proaches, these
nt issues, but touched
included Dr. Eric
the marketin
said. Indian replacemenrelied on training their future
“And I appreciated
on the
Topol, director of
est portion of
of agriculture as
the way we were
ts. (Senator Bill Nelson
the
Scripps Translation
able of Florida has
mounting challenges poor countries face
al Science Institute to work on various things.”
called
for
an
investigation of
in La Jolla, Calif.,
On the topic of
the abuses of the H-1B
ple; and the recent in feeding their peoauthor of “The Patient
managing growth
visa
Ebola epidemic, which
Will See You Now”
AUGUST 2015
in
In raising the numbers program.)
shows
and one of the keynote a sustainable way, Clinton talked
32 MED AD NEWS
luncheon speakers
of H-1B visas systemsthe need for establishing healthcare
about while he
at BIO; Dr. Ezekiel the lessons he learned from The
was
Emanuel, speaker
Clinton intent was president, Clinton said the contrast in African nations without one (in
Foundation, which
on
to benefit biotech
for several years
and the transforma healthcare reform the fastest-grow
and other one case to its neighbors, Nigeria only had
was STEM industries
of Ebola since it showed
to allow talented
medicine; Dr. Ron tion of American in the world. ing organization of its type uate students
grad- wealthiest
Cohen, event co-chair,
“It’s a constant challenge
to be employed
area of the country, up in the
incoming chairman
manage growth without
by U.S. good healthcare,
to companies. Replacing
which has
of BIO, and CEO
losing the
and workers were
U.S. workers with
Acorda Therapeuti
of
able to
track down and isolate
cs Inc.; Janet Wood- that animated the company in vision contractors, however, “is
not the culture
cock, director of
the first I believe
place, and what worked
tient had been in contacteveryone the pathe
is productive for
best, I believe, is
Evaluation and ResearchCenter for Drug a culture of
America over
with).
the long run.”
constant commitmen
He joked about the
Daniel Kraft, inventor at the FDA; Dr. mission, constant
t to the
Clinton advised the
ing of some words change in the meanand entrepreneur,
creativity, and constant
corporate leaders
in the modern world.
and founder of
cooperation,” he said.
Bioniq
“There’s a mountain in the audience that “The best companies “Lee [Segal] stood up on this
is focused on enabling Health, which full of social
stage and
have to do
said
science evidence and
scientific to pursue three things at once. You’ve got that I was a disruptor, did you ever think
driven and integrated connected, data research that
shows groups of people
would
the mission that
cine; Bob Hariri, CEO personalized medi- better decisions
you got into a disruptor become a popular word? I was
make business to
in grade school too.
Therapeutics; Martine of Celgene Cellular say that with than lone geniuses. And I to manage do in the first place. You have me
All that got
some humility, if
was
Rothblatt,
the
bad
day-to-day,
grades
founder
in conduct.”
the IQs in incoming
of Sirius XM Radio;
including the
this room were translated
Positive disruption
and management
to pounds, the important fire. And the third thing that’s
gu- floor would
rus Tom Peters and
interdependent world is great, “but in an
collapse. But
Gary Hamel.
to do is we have to
where all borders
According to Klick
keep taking look
Clinton pointed out it’s really true.”
some time out to
CEO Leerom Segal,
more
“Health and technology
as one of the 10 most how Klick was cited around the corner,look down the road and cape the like nets than walls, we can’t esare advancing at
intrusion of negative
admired corporate
to
such an exponentia
cultures, one of
forces.
ture. Imagine what think about the fu- very often, just
l
I think it’s going to
as there are no final But
rived at an amazing rate and we’ve ar- one of the 10 the 10 best employers, and
be ries, there are
victobest places to work.
no final defeats.” medadnews
their convergence. inflection point in counts for
Pharma
something,” he said, “This
Ideas Exchange
will that the trend
touch on cutting-edg
adding
TWO EXECUTIVE
that has placed shareholde
CHANGES AT OCHWW
gies that are shaping ideas and technolo- ers over stakeholder
the
•
Bill
Mordan
is
now
general
counsel
and
future
s
(such
of
digital
as
health – from 21st
employBy Christiane Truelove • chris.truelove@medadnews.com
Ogilvy CommonHea
century cures, person- ees) has eroded corporate and
corporate secretary
of Shire, reporting
to
lth Worldwide
workplace
has appointed Michael
cultures. He called
CommonHea
Flemming
Ornskov. Mordan
alsoMarketing
serves
out the loopholeCEO
lth Payer
Zilligen as president
in the
and
of
both
Ogilvy
Ogilvy
Healthworld
Graham to
E
g
Digital Marketin
Interactive and
”role to
on“orchestrator nce
Sales reps take
erie
r customer exp
deliver superio
A
1
june
august
5
2
Medicine Avenue
Klick Ideas Exchang
3 e powers
kickoff of BIO conventi
on
s
STATE OF THE BIOTECH INDUSTRY
s PAYER ACCESS
s DTC
s HBA WOTY COVERAGE
s TOP 200 MEDICINES
s YEAR AFTER LAUNCH
s
PHARMA LEADERS OF INNOVATION
LIONS HEALTH TAKEWAYS
s
Ad Close: 5/04/16
Materials Due: 5/11/16
Ad Close: 7/03/16
Materials Due: 7/20/16
october
december
O
4
People On The Move
VP AT HCB HEALTH
New CFO, financial teamNEW
members,
atCHICAGO
Purdue Pharma
J
Greg Niemczyk
Payer Marketing, and
as a member of the Shiregeneral
executive
commit-of
manager
Ogilvy CommonHea
Zilligen,
lth Specialty Marketing. promoted Amy
who
tee. He joined Shire
from
Reckitt
mostBenckiser
recently held the position
Marketing,
of president at Ogilvy
hands
Group plc where
he served
as the
group
genreins
CommonHealth
over to Graham,
Specialty
CommonHea
as he assumes the
has joined HCB
eral counsel and
corporatelth
secretary.
ean-Jacques “JJ” Charhon has ness
joined
Worldwide’s payer
top leadership role
marketing agencies
development. Niemczyk Health as a VP, account director/busifor Ogilvy
will focus
housed in New Jersey.
Shire alsoZilligen
appointed
Michele
Galen asclients
Purdue Pharma as executive VP and chiefoffi
finanis based out of HCB
on helping
In his
ce,
address the strategic
care reform;
bringing new and
implications associated new role,
head of Corporate
Communications
cial officer. Charhon is responsible for the
com-and also shares responsibility for growing Health’s Chicago
innovations to the
base.
the agency’s client
with healthHe reports directly
access
organization’s offering
services,
Public Affairs,
reporting
to biosimilars,
Ornskov. Galen
pany’s financial, procurement, and information
to agency partner
in areas such as patient
systems of care, and
working closely with
Nancy Beesley while
real world evidence;
Chicago’s
and
additionallylaboration
serves as an
extended
member
technology functions.
integration
and driving continued
with Ogilvy CommonHea
“Greg has a tremendous President Al Topin.
icut-based
collth Market Access,
of the Shire
executivepayer
committee.
“JJ is a proven leader with experience in the pharmaceutical,
reputation in the
group. Galen
the network’s Connectpharmaceutical growth
industry for sparking
more
in both the professional
most recentlyWith
served
as athan
managing
direchealthcare, and technology industries,” says Mark Timney,
25 years
of industry experience,
segments,” says Kerry
and direct-to-patient
Zilligen has expansive
Hilton, CEO and partner
the corporate
tor for MPMpertise
Capitalinand
president and CEO. “His expertise and proven recordHCB
of suchealth-careadvisor.
arena, on both the
knowledge and exof HCB Health. “We
Health are impressed
began
client
his
and
at
career
service
by his accomplishm
Both the general counsel andatcommunicacess leading finance organizations will be a valuable services
asset to
sides of the business.
Ogilvy CommonHea
ents in both account
and agency managemen
lth Worldwide nearly
Zilligen
Greg Niemczyk tions roles marketing
are based atdiscipline
Shire’s headquarters
Purdue’s growth strategy.”
10 years ago within
t, and are fortunate
and was instrumental
get back to his Chicago
the payer
that his desire to
in helping the agency
years.
Zilligen will report
roots coincided with
in Lexington,
Mass.
Charhon joins Purdue from Cnova, one of the largest Niemczyk
global
succeed during its
directly to Shaun Urban,
our growth
formative
Worldwide, who oversees
managing partner
eCommerce companies, where he served as executivedirector
VP and came to HCB from GSW and its oncology aspirations.”
at Ogilvy CommonHea
the organization’s payer
in the Columbus
partner Navicor, as
developmen
lth
marketing, medical
groups.
• Brian Hilberdink
hastbeen
given the role
chief financial officer, with responsibility for investor relations,
senior VP, account
education and business
teams in the immunology office. His contributions ranged from
leading domestic
has been
, oncology, nephrology,
of president,Graham
Novo Nordisk
Canada
Inc.from
He
planning and external reporting.
elevated
and global
ness that elevated
executive VP, director
and pain categories
ofheld
Ogilvy
both revenue and
of client services, to
to generating new
the CommonHea
position of VP,
Before joining Cnova, Charhon worked for four marketing
years at
lthDiabereputation for
Worldwide’s full-service
busi-previouslycompany
general manager
professional advertising
andfocusing
Market on
Access,
Novo
Hewlett Packard, where he joined as chief financial demonstrate
officer of experience spans professional to patient the agencies. His extensive integratedtes Marketing
high-science
and promotion
and specialty areas.
and pharmaceuticals
operations,
strategic
In
Prior
to this
role, Brian
the PC division before becoming chief operating officer
of En- d ability to identify and decipher communicat
to biologics, with aNordisk Canada.
planning
and new business initiatives her new position, Graham leads all
providers
and patients.
Marketing, expanding
ion challenges among
for Ogilvy CommonHea
Marketing,
Novo
terprise Services, a $23 billion division of HP. This role followed
upon the
health-carewas corporate VP, Global
group’s therapeutic
Before joining GSW
lth Specialty
Graham
breadth and client
and Navicor, Niemczyk
Nordisk A/S,Ms.
and
led thehas
commercialization
eight years at General Electric and four years at Novartis,
where
been with the network’s
roster.
Chicago,
served as VP, account
where he managed
specialty agency for
20 years of future
director at
experience
of the company’s
insulin
portfolio,
he held various global financial leadership roles of increasing
overall client-agency
two years and has
in the
pharmaceutical industry.
relationships and developedAbelsonTaylor in
more than
partner responsible
She reports to Darlene
development
untilCommonHea
the
responsibility. His last role at Novartis was global head of Busifor Ogilvy
new business. from Phase II clinical
Dobry, managing
lth Worldwide’s medical
ketinginand
medical
first launches
Europe
andmedia
Japan.groups.
He also
ness Planning, Analysis & Investor Relations.
marketing, specialty
marhas experience working in the United States
Charhon earned his baccalaureate in Math, Physics
& Chem34 MED
AD
where, as director, Brand Management, he
istry at the French Lycee of Brussels. He holds a master’sNEWS
in AUGUST 2015
led multiple brand teams during a period of
business administration from the Universite Libre de Bruxelles
significant growth for Novo Nordisk U.S.
– Solvay School of Management.
In addition to Charhon, Thomas Leggett comes aboard
• Julie Monzo has been appointed to the
Purdue as treasurer and head of Business Development Finewly created role of senior manager,
nance with responsibility for business development opportuGlobal Medical and Development (GMD)
nity evaluations, capital markets activities, and management of
communications, of Astellas’ corporate aftreasury and insurance operations.
fairs department. Monzo will report to AnLeggett joins the company with a broad range of investdrew Lewis, head of communications, GMD,
ment banking experience. He was most recently an executive
Jean-Jacques “JJ” Charhon
and will lead internal and external global
director and one of three senior calling officers leading the
communications programs for the funcbiopharmaceutical investment banking coverage effort in the
tional groups that comprise GMD, includAmericas at UBS Securities LLC. Prior to UBS, he worked in Dan holds a bachelor of arts degree in accounting from Rutgers
ing Clinical Development, Medical Affairs,
healthcare investment banking at Lazard Freres & Co. and J.P. University, a J.D. from Boston College Law School, and an LLM
Pharmacovigilance, Quality Assurance, and
Morgan Securities Inc. Leggett holds a master’s in business ad- in taxation from Boston University Law School.
Regulatory Affairs.
ministration from The Wharton School and a bachelor of arts
Edward Mahony is assuming the role of executive VP for
Monzo most recently served as senior
degree in economics from Columbia University.
Due Diligence & Integration Management, with responsibility
manager, enterprise communications and
Dan Russo joins the company as tax officer with responsi- for optimizing the value of potential and completed business
public relations at the College of American
bility for all tax matters, including business development tax development transactions. He began his career at Purdue in
Pathologists.
structuring. Russo most recently was VP Tax, Americas for Dia- 1993 as VP and chief financial officer, and was promoted to exgeo; tax director for ITT Corp.; and tax counsel at Xerox Corp. ecutive VP and chief financial officer in 1999. medadnews
Health O
utcome
s
By Med
Ad New
s staff
Developi
for toda ng value-added
y’s empo
str
wered pa ategies
By Amy
Parke
tient
Specialty Pharma/Specialty Biopharma
Meeting
the
challenge
of
physician
In order
and patie
to
the disea successfully impac
nt colla
boration
se journ
t outcoand
focused
on ey.
theJust
development
• Briggs W. Morrison, M.D., has joined Syndax Pharmaceuticals • Robert L. Rosiello was appointed as executive VP and chief fi- biopharmaceutical company
does the
along the
as the patienmes, physicians
physician.
journey
treatments
for liver
and infl
ammatory
Inc. as CEO and a member of the board of directors. Michael A. nancial officer at Valeant Pharmaceuticals International Inc. Rosi- commercialization of novel
must collab
gener
Altho
t needs
al popu
ugh
support
orate with
Metzger has become president and chief operating officer. Dr. ello worked 30 years at McKinsey & Company helping healthcare, diseases.
technologie lation in smart physicians have
from
phone adop
been quick multiple sourc their patient along
Morrison came from AstraZeneca, where he was executive VP of technology and consumer companies deliver growth through
bring the s such as FitBit
es along
to
tion for
into the
same
the way,
example, adopt technology
journ
hast,been
made
chief
business
offi
cer of
patien
Global Medicines Development and chief medical officer. Metzger M&A and business unit financial performance improvement. As • Bob Goodenow, Ph.D.,
patien
so
ey mapp
they are
, outpa
the physi
ing approwast’s overall care
cian travel
illustratesMost
recently,
Dr. Goodenow
joins from Regado Biosciences, where he served as president and senior partner in charge of the global merger practice for the past Huya Bioscience International.
plan. To slow to incorporatecing the
ach to
s a path
a hypot
help for
hetical physi
in unde how they intera address this, pharm new
at Syndax
Huya
Bioscience
spe- chief business officer realiz
CEO through the company’s strategic merger with Tobira Thera- decade, Rosiello led M&A integrations
to pharmaceutical,
ation,Pharmaceuticals.
identify
rstand
ct
with
consi
cian
mean
ing and
new
physicians. a needs to
relev U.S., International is a leader
derataccelerating
journ
differinent
enabling and
global
cialtydyna
pharmaceutical, and medical device
companies
peutics Inc.
ingfu
ion, action the
ey which
treatin
l contein the ant
channels
mic has
channels
Just like
could encom g a disease.
and accep
nt
conte
the
evolved will provide
development of novel
biopharmaceutical
product
opportunities
Europe
Syndax is a privately held biopharmaceutical company lever- over
the and
nt and suppoto obtai
tance –
pastAsia.
n conte
pass phase The figure below
the patiefor each stage and
deca
supp
where
in
nt.
bette
rt
de
By
the
ort
originating
in
China.
Valeant
Pharmaceuticals
International
is
a
multinational
speaging recent scientific insights on its lead therapeutic candidate
s such as
in
that
in each
makin
withr equip
throughou nt with the
healthcar
awareness,
phase the
the physi each channel where g it easy –
mark
For
e deliv
proper
t the journ
cialty
pharmaceutical
company
that
develops,
manufactures
and
entinostat in the emerging field of immuno-oncology.
example,
cian to collab
etpla
ery chro
and when delivering appro physician turns
ey.
patie
Norange
do markets ce.
blindly
orate with
priate educa
nic cond
to
nts diagn
of-patien the physician
broad
of rpharmaceutical
products
primarily
in • Martin J Birkhofer, M.D., has been appointed chief medical
longe
ntsasit
follow direcpatie
ition such
osed and Professor Chris McGuigan is now chief scientific officer
tional
go
needs it
meekly
ts along
are more
categories
eyethrou
health,
and brand• Charles Stacey, M.D., is now president and CEO
of Accera
Inc. the
tion.
– pharm
as diabeficerwith
ghneurology
their journ
and ease
a
Toda of dermatology,
likely
five majo
a will
tes
menmanager
ey.
migh Birkhofer joins NuCana from inVentiv Health Clinical,
journ
r
at NuCana.
ed generics. y’s patie
Before joining Accera, he was a senior investment
withto arriv
t
A
informed
s TOP 50
PHARMACEUTICAL COMPANIES
s COMPANY OF THE YEAR
s HBA ANNUAL CONFERENCE PREVIEW
Ad Close: 9/09/16
Materials Due: 9/16/16
s
AD AGENCY ROUNDTABLE
s MOBILE MARKETING
s NEW VENTURES
Ad Close: 11/09/16
Materials Due: 11/16/16
e at their
nts
ey, inclu
phases
in
t
to enga
1. A
the disding
appo
where
he led its global medical and scientific affairs and held the
London-based Inventages, one of the world’s largest
lifegesciences-about their
with
disease, int- fraught recognition of :
an activ
Duke Jr.read
is now
financial
officer of Pulmatrix
Inc. title of chief medical officer. Professor McGuigan was the original
focused venture capital and private equity firms.
Accera
clinical-their• William
with
initia
physician
e arole
y chief
l
denia
ing and
in the treat
and
tomsof the ProTide technology and was professor of medicilack Inc. symp
of their
inventor
Dukemen
previously
served
financial officer ofl,Valeritas
stage biotechnology company developing ing
therapies
for central
takeas chief
In this possible impact of undenal
to a study conditionPulmatrix
track
chemistry
at the Cardiff School of Pharmacy and Pharmaceutiist aand
clinical
stage
company developnervous system disorders.
phase they
d. Indeed,
on socia rstan
- biopharmaceutical
tion
Center, published by
l cal
acco
statu
arepulmonary
rding therapiesand
Sciences. He is additionally the chair of the Life Sciences Hub
ingthe
innovative
inhaled
to address serious
72 perce
Pew Rese
diagn reassurance andseeking informa-s.
Inter
nt ofdisease
net indic
Wales Ltd.
its patented
technology.
• Iain Ross has been appointed acting chief
executive
and has
arch iSPERSEosis
peopusing
news outlesites, their frienmay turn to selfle
ated
line
NuCana is a rapidly growing, clinical stage biopharmaceutical
been reappointed to the board of Novogen
Ltd.for
Ross
is currently that they using the
ds
healt
ts, and
h infor
looked Ph.D., is now
fami
2. AVP,
patient andand
perceknown
lies, with a broad development portfolio of novel anti-candiagn
company
• Ian
investor
relations
chairman of Premier Veterinary Group PLC70
(formerly
as Ark mati
onlincornt of U.S.
on Clements,
osis and
e forum
in 2012 on- phase,
at least
treat
again
at Tobira
Therapeutics
Inc. men
Dr. Cle- cers.medicines. The company’s proprietary ProTide technology has
Therapeutics PLC), a non-executive director
of Amarantus
Biosci-adulporate
and lack
one healt
ts saycommunications,
wher
t
influ
on
they
h indicments
there is com- ence
of relations
the for Anatara Lifetrack
understan
the potential to set new benchmarks in efficacy and safety with its
previously
led investor
ande corporate
ence Holdings Inc., and a non-executive director
ator. Phys
denial and
r hand
peer press
pressed othe
ding was
icians, Pharmaceuticals
withrecently
that are specifically designed to overcome key cancer
sciences Ltd., Benitec Biopharma Ltd. and Tissue
Therapies Ltd., overb
a
for
rampedtreatments
urdenedat Avanir
andwhich
best cour ure Inc.,
time and munications
disea
inde
se
up
and Pharmaceutical
mechanisms.
clinical
stage resistance
Novogen is a public, Australian-U.S. drug-development
company. acquired
seCo.
managem
outco by Otsuka
of Tobira is a cisiv
enes
working
actio
mes-base
s
pharmace
ent, are
with their n. Here patie on the
resources, utical industry looking to d tion webs
nts are
physician
the or
ites
, informatients need direction and to provide
insurance and possibly
the men
their
prove their to best man education
t optio company on poss employer
paage and/
ible treat
3. A decisns.
Addressincondition.
or imare work ion making
cant chall g this dilem
phas
ing with
phys
with these enge to the ma is a signi
their phys e where they
fi- to ician’s office
ician and
burdened empowered industry. Face
staff
better
patients
d
understan as well as webs the
no longe physicians,
and over- and its side
d
ites ily
their
the
r
treatmen
understan
find ways mandate treat industry can changes theyeffects as well
t emb
as the lifest
may need
itself and to bridge exist ment but must might be
race basicdable. To do so,
yle
to
we need
learn
it serve the physicianing gaps between how to get addressing needmake. Patients as those in
to
the follo ing principles
s.
educated
le
properly
Equally
all parti True colla s and patie
4. An Initia
such
wing chec
at hom phobia or
important
bora
nts
corre
e.
our audi address the
change es will be need tion between begins perh tion phase wher
to
health klist, and wher ct content is
ence throu
the conv
ed
aps reluc
literacy
e treat
connectincreating the
e they
ghout their
value adde
ersation to ultimately tient deals
with lack tantly, and thement Checklist
journey. of mation. Thiswould most likelyg to people
to deliv
or
and need d strategies
of nurs
pa- of heal for impr
can rang
that patie er the on at-home educ
seek infor
in their
ovin
manage to better unde
th infor
ation. Quese follow up
disease
e
mation g the usability
their disea
rstand, nts want and
disease physician’s officefrom brochure prog
track and
websites
online suppression and tions arise
s
se.
to bran
•
Iden
forms.
peer
tify the
ort is often
s’ advic
Creating
5. An
Each chan and social med d and
• Use preinten
e
content,
the pati
nel will
ia platphase wheradherence and sought.
and post ded user
• Limi
ent jour
within tailored to engarequire its own
ney map face fatigue e those using injecmanagement • Use t the number tests s
In orde
that
r
plain
ure 1 dem channel envirge the patie
tables often
bile apps and adherenc
between to foster a colla
• Practice languageof messages
onment. nt
activities onstrates the
borative
respect
and the for tracking e drops off. MoFig• Focu
pursue all parties, the
spiri
may
patient
a
2017 accomost likely to patient outreach
• Checks on behavior
looks for be employed
and use holistic appr industry needs t port from
increase
rding
for und
oach to
emot
careg
to advic
issued
• Suppleme
erstandin
it comm this approach
treat
in 2012 to a Cutting Edgethrough
e forum ivers, friends ional supas a basis ment
unicates
sona
–
nt
g
s.
•
a comb
and patie
Use a med with pictu
report
l and
sician. Dise
to both
for how
nt
emphasis digital conta ination of peror translatoically train res
body and ase impacts patient and phy- The righ
cts with
on apps
ed inter
t content
far more
r
As the
a heavy
.
preter
A case
sis to curethe patient alone
than the
in the righ
in poin
current U.S populatio
t is the
Understan
t place low, developed
lows a reall or end of life, . From diagn
baby boom
n matu
oding
reach
the patie
Control
by the Centflyer shown
and devia y long road
be- cial activities will ers are repla res and
nt fol- patients go throuthe steps and
–
the flyer and Preventio ers for Dise
media and
diagn
incorpora ced, outemot
gh
style, by tions; one chanone with bum
ase
n.
employ
ps the osis and treat in dealing with ions grap
income,
ged by
simple Not only does er, more conv texting, requ te more sohard, perso
hics
discussion
learn
ment helps
by
their
iring a shor
ersat
was deve to illustrate thelanguage and use dynamic
nal stuff family dynamic. ing ment
and
to fram
as such
tto enga ional communica
loped in
and must
main poin
e
It’s dress of much more lead to the
.
ge the patie
mult
develop- support all
tion
be treat
In orde
valuable
nt.
ed Once ing patient
demogra iple languagests, it Harnessi
r
Unit
conte
to
with mean
concerns
ed State
phic grou
respond
nt
ng tech
to
creat
s.
at each adps in the patients’
appropria
nology
tered, aggreed, it shou
pharma ingful tools
step.
lives easi
ld be
to make
tely
and
er
the emotneeds to captu conversation, ingful way) gated and colla curated (filAs show
the disea ional and physre data on both out the varioand then synd ted in a mean
icated throu embrace n in the chart
us chan
wher
ney. Aspese all along the ical impacts
below,
the race
of migh ever patients nels to offer expo ghcare is technology to
patient’s
diet and cts such as
and their
t turn
sure
jourmed
cial med on. Informati improve healt to
caregivers
lifestyle exercise regim ical routines,
However,for education
ve webs
hia platf
and
on
custo
ens,
orms
ites,
creat
supp
smar
to
ms, key
well as
,
work
dissemina
ing
soort.
impact
relationsh and and
tronic tphones, note the use of apps
te, conte the right conte
on the patie
should
devic
understan
ips,
nt that
be
AppleWa es such asbooks and elecis enga nt
dable,
lyzed. Fromcarefully mon nt’s self wortas Indeed, the
tch are
h a long
pharmacecan be a chall ging
creating FitBit and the
this data, itored and
patient
new optio
utical indu enge.
histo
anajourn
like contr ry of creat
ns for
into a conc ey map thatone can creat
ing ads stry has
e
acts, webs
that
Such map ise, visually distills insig a social med
ites that
compelling hts antiPatient
ia
look like look
assistance
that patie s highlight the
social interfaces that
ads,
story
dosing
programs
email
11%
taking nts will go throudifferent stage . erally need and using langu are actually
Education
5%
action
Patient
s a phys
al
s thou
age that
gh from
website
support
to
disease.
groups
11%
As such finally managingbefore deve gh much conteician to interpret.gen11%
, patient
loped
nt
journey their vironmen to address creation has AlText messages
Patient
advocacy
been
maps
the
6%
groups
6%
do much t in which we regulatory
38 MED
ento make
AD NEWS
oper
Reminder
our conte ate, we can
AUGUST
calls
2015
11%
nt more
read-
36 MED AD NEWS AUGUST 2015
Apps
39%
PharmaLive.com returns as the pharmaceutical industry’s #1
destination for news and analysis and delivers the most comprehensive
and collaborative community for pharmaceutical marketing
professionals. PharmaLive.com offers sleek and reliable navigation and
the ability to share, comment and contribute content.
Covering ...
• Business • Marketing & Advertising
• Therapeutics • R&D • Resources
es:
File Siz .,
x
50k ma
s
4 frame
max.,
g:
Loopin x
ma
3 loops
Ad units:
• Interstitial – 640x480 pixels / $2200 net/week
• Rectangle – 300x250 / $2500/mo
• Charter Program – 728x90 Leaderboard and
Footer, 300x250 Rectangle / $4400/mo
Accep
ted
GIF, An Formats:
imate
JPEG, H d GIF,
T
Flash, U ML,
nicas
PointR
oll, Eye t,
blas
Enliven
, Bluest ter,
Motif, V reak,
ideo
Rich M
e
accept dia is
ed for a
n
additio
nal $50
0
Daily Advantage – 20,000 Distribution
The PharmaLive Daily Advantage eNewsletter is the most
relied on daily news source in the pharmaceutical industry,
providing 20,000+ readers with the day’s most important
news and information.
Leaderboard - $6500/month
Rectangle - $4500/month
Anchor - $3950/month
Featured Company - $2500/month
Medicine Ave News (Weekly)
Covering all the latest happenings within the healthcare
communications world, including agency perspectives,
upcoming events and game-changing developments
impacting healthcare marketing. 15,000 weekly
Leaderboard - $3100/month
Rectangle - $2200/month
Featured Company - $2200/month
Med Ad News Digital Edition
Med Ad News Digital Edition expands your reach to an additional 20,000 bonus audience via desktop
and upgraded mobile format. Enhance with: Video: $800 / Leaderboard: $1200 / Button: $600
Page
Views
Total
Visits
Page Views
per Visit
306K
17.4K
17.6
New
Visitors
Avg Visitors
per Day
Avg Time
on Site
11.1K
43.6
5m 9s
Custom Email Campaign
PharmaLive.com eBlast Marketing program delivers your branded message to your ideal demographic.
Target by business type, job function, geography and more. - $450 CPM
o
ow what t
n
k
’t
n
id
d
“I
year, but
is
h
t
t
c
e
p
ex
o
omerun. S
h
a
s
a
w
this
tinue the
n
o
c
o
t
y
happ
.
tradition”
n
e
e
b
s
a
“This h Manny
t
s
e
b
e
h
t
!”
t
e
y
s
d
r
Awa
Each year, agency
professionals come together
to recognize significant
contributions to, and celebrate
creative excellence in,
healthcare communications.
On this special evening, more
than six hundred industry
peers will join Med Ad News
in honoring jury-elected
nominees and winners in a
range of carefully selected
award categories.
For over twenty-five
years, the Manny
Awards have paid
tribute to the creative
work of agencies
serving the healthcare
market, their people,
and their contributions
to the industry.
mannyawards
Thursday, April 21st, 2016
This unique event is one you cannot miss.
Include your branding alongside this prestigious event and reach an
audience of engaged advertising professionals.
Contact your account manager today!
mannyawards.com
rates and sizes 2O15
1/2 COVER
OUTSIDE
FLAP
LIVE AREA:
5” X 11.5”
TRIM:
5.5” X 12”
BLEED:
5.75” X 12.25”
KING PAGE
KING SPREAD
LIVE AREA: 10.375” X 14”
TRIM: 10.875” X 14.5”
BLEED: 11.125” X 14.75”
LIVE AREA: 21.25” X 14”
TRIM: 21.75” X 14.5”
BLEED: 22” X 14.75”
1X
2X
4X
6X
1X
2X
4X
6X
$8395
$7800
$7500
$7195
$15,885
$14,700
$13,500
$12,950
1/2 COVER
INSIDE FLAP
LIVE AREA:
5” X 14”
TRIM:
5.5” X 14.5”
BLEED:
5.75” X 14.75”
1/2 KING PAGE
1/2 KING SPREAD
TRIM: 10.875” X 7.25”
BLEED: 11.125” X 7.5”
TRIM: 21.75” X 7.25”
BLEED: 22” X 7.5”
1X
$16,400
2X
$15,300
3X
$14,700
1X
2X
4X
6X
1X
2X
4X
6X
4X
$13,750
$6825
$6500
$6200
$5900
$12,350
$11,175
$9800
$9500
1-SIDE TAB
DIVIDER
(APRIL)
1X
$9000
2X
$8500
3X
$8300
4X
$8000
JUNIOR PAGE
JUNIOR SPREAD
LIVE AREA: 7.375” X 10.375”
TRIM: 7.875” X 10.875”
BLEED: 8.25” X 11.125”
LIVE AREA: 15.735” X 10.375”
TRIM: 15.735” X 10.875”
BLEED: 16.078” X 11.125”
1X
2X
4X
6X
$6825 $6500 $6200 $5900
1X
2X
4X
6X
$12,350
$11,175
$9800
$9500
Why Choose MedAdNews?
n Reach senior level pharmaceutical and biotech professionals
n Extended reach in print, online, email and event marketing
n The industry, your customers and colleagues
demand our unparalleled content
Outcomes LLC
16 Prospect Road
Livingston, NJ 07039
973-507-6701
Outcomes LLC
A marketing and media company built to quench the evolving consumption habits of B to B audiences.